The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) has a mission to develop safe and effective contraceptives for women and for men. The Contraceptive Clinical Trials Network (CCTN) was established to provide qualified sites the ability to perform clinical trials of new products, including a Statistical and Clinical Coordinating Center (SCCC). Progestogenic androgens are a class of drugs that can bind both the androgen and progesterone receptors with varying affinities. By promoting low circulating levels of gonadotropins via hypothalamic and pituitary arrest, the normal mechanisms for ovarian follicular maturation and release and sperm production are impaired. NICHD has sponsored studies evaluating progestogenic androgens in phase I and IIa clinical studies in healthy cis male volunteers, which established its androgen action, favorable safety profile and acceptability. Consequently, given its contraceptive potential, potent androgenicity, and lack of significant safety concerns, progestogenic androgens may be an ideal candidate for use in diverse populations as well. Examples of agents in development within the Contraceptive Development Program (CDP) include dimethandrolone undecanoate (DMAU), levonorgestrel butanoate (LB), 11- beta-methyl-19-nortestosterone dodecylcarbonate (11-beta-MNTDC), and other entities in preclinical development for use as a novel contraceptive product. The purpose of this Task Order is to conduct work required and to provide the appropriate deliverables associated with the completion of ongoing and new early and late phase clinical trials designed to investigate progestogenic androgens for contraception. This task order will support the coordination, monitoring, data analysis, and all other associated activities of ongoing and new clinical trials in the evaluation of progestogenic androgens as contraceptive agents in different populations. All sites will transfer data to the SCCC. After study completion, the SCCC will collect the data and perform data analysis and prepare a clinical study report suitable to support regulatory guidelines pursuant to eventual FDA approval of the new drug. The proposed task order will provide coordination of protocol approval, clinical trial conduce, oversight and monitoring, data analysis and a final clinical study report for the supporting regulatory approval of the product for contraception.